• Contact Us

Registration for ASGCT's 28th Annual Meeting is NOW OPEN! Join us May 13-17 in New Orleans for the premier event in CGT.

• Annual Meeting
  • Register
  • Sponsor & Exhibit
  • Future Annual Meetings
  • Annual Meeting Archives
    • 27th Annual Meeting Video Archive

  • Program
    • Workshops
    • Keynote Speakers

  • Abstracts
    • Present
    • Awards
    • Topics
• Membership
  • Video Library
    • Annual Meeting
    • Cancer
    • Career Skills
    • Gene Editing
    • Patients and Clinicians
    • Regulatory
    • Viral Vectors

  • Become a Member
  • Economy-Based Rates
  • Awards
  • Membership Directory
  • Scientific Committees
  • Standing Committees

  • My Profile
  • Career Center
  • ASGCT Abstracts
    • Abstract Submission Windows
  • Volunteer
• Events
  • Around the World: Advanced Therapy Medicinal Production in South America
  • Molecular Therapy Presents: Extracellular Vesicles
  • Empowering Patients 2025: A Cell and Gene Therapies Summit

  • Breakthroughs in Muscular Dystrophy
    • Registration
    • Abstracts
    • Program
    • Speaker + Attendee Resources
    • Sponsorship

  • Class Considerations on Immunogenicity for AAV GT Products: Assessing Current Practice + New Data
  • Professional Development Cafés
  • Non-ASGCT Events
• Awards
  • Honorific Awards
    • Outstanding Achievement Award
    • Outstanding New Investigator Awards
    • George Stamatoyannopoulos Mentorship Award
    • Award for Excellence in Advancing Diversity, Equity, and Inclusion
    • Exemplary Service Award

  • Annual Meeting Awards
  • Underrepresented Populations in Gene and Cell Therapy
  • Mavis Agbandje-McKenna Scholarship and Fund

  • Career Development Awards
  • Congressional Policy Fellowship
• Outreach
  • Clinical Trials Finder
  • Community Quick Takes
    • Informed Consent
    • State of the Field Highlights + Approvals for CGT in 2023
    • Access to Approved Cell and Gene Therapies
    • Genetic Testing and Clinical Trial Eligibility
  • Diversity, Equity, and Inclusion
    • Biotech Discovery Labs Program

  • Patient Education: Gene Therapy 101
    • Gene Therapy Basics
    • Gene Therapy Approaches
    • Clinical Trials Process
    • Vectors 101
    • Gene Editing
  • Global Outreach

  • Patient Education: Condition Treatments
    • Beta Thalassemia & Other Blood Disorders
    • CALD and MLD
    • Spinal Muscular Atrophy
    • CAR-T Basics
    • Hemophilia
• Publications
  • ASGCT Blog
  • The Patient Press
    • December 2024
  • The Vector
  • Quarterly Gene, Cell, and RNA Therapy Landscape Report

  • ASGCT Podcast Network
    • Giants of Gene Therapy
    • The Issue
    • The Molecular Therapy Podcast
  • The Advocate
    • Subscribe to The Advocate

  • Molecular Therapy Family
    • Molecular Therapy Presents Extracellular Vesicles
    • Cell Press Webinar: Advances in Viral Vector Gene Delivery for CT Biomanufacturing
    • Molecular Therapy
    • MT Methods & Clinical Development
    • MT Nucleic Acids
    • MT Oncology
• Advocacy
  • Events and Opportunities
    • Policy Summit
    • ASGCT-FDA Liaison Meeting
    • Cell + Gene Therapy Science Series
    • Congressional Policy Fellowship
    • FDA & ASGCT: Immune Responses to AAV Vectors

  • Policy Priorities
    • Patient Access Overview
    • Regulatory Policy
    • Research Funding

  • The Advocate
    • Subscribe to The Advocate
  • Policy Statements & Letters
• About
  • Leadership
    • Board of Directors
    • Scientific Committees
    • Standing Committees
    • Staff
  • Work at ASGCT

  • Media
  • Our Culture
  • Strategic Plan
  • Meeting Code of Conduct
  • Terms and Conditions

  • Mission & Vision
    • Bylaws
  • Support ASGCT
    • Annual Meeting Support
    • Advertise in ASGCT Publications
    • Digital Programs
    • Giving
    • Year-Round Support

2024 Archive

Read and Download 2024 Reports

Learn about new approvals and the state of the field for each quarter of 2024.

Q1 2024

The field earned the approval of three new therapies—a CAR-T therapy for myeloma in China, an AAV gene therapy for hemophilia B in Canada, and an autologous cell therapy for melanoma in the United States.

Read the Report

Q2 2024

In Q2, two new RNA therapies were approved in the US; Rytelo was approved for myelodysplastic syndrome and mRESVIA, an mRNA vaccine, was approved for respiratory syncytial virus (RSV) prophylaxis.

Read the report

Q3 2024

While we saw only one new approval (Tecelra for synovial sarcoma), there are dynamic shifts deeper in the pipeline. The field is steadily diversifying; 51% of newly initiated gene therapy trials are now for non-oncology indications, up from just 39% year-over-year.

Read the Report